Current and Future Programs Summary



Discovery platform

- Access to pioneering platform
- Scientific capabilities and outstanding team

Revised filgotinib collaboration

- 50/50 global development costs split
- Broader European commercial role for Galapagos

GLPG1690 (IPF): license for ex-European rights

- \$325M milestone upon U.S. FDA approval
- 50/50 global development costs split

GLPG1972 (OA): option on U.S. rights after Ph2b

- \$250M opt-in
- Up to \$750M in milestone payments

All other clinical programs

- \$150M opt-in
 payment after Phase
 2 for ex-Europe
 rights
- 50/50 global development costs split post opt-in





Inflammation

Filgotinib Marks Expansion into Inflammation with Potential for 5 Launches in Next 4 Years

Filgotinib


Selective JAK-1 inhibitor with potential best-in-class profile

Strong efficacy for remission and demonstrated safety at both doses; favorable benefit/risk profile at high dose

Submitted for RA in U.S., Europe and Japan



COVID-19 Insight: Filgotinib for RA filed with regulators globally, including U.S., Europe and Japan. We are continuing to prepare for launch and are in close contact with regulators to understand the effect that COVID-19 could have on review timelines.



Preparing for competitive RA launch with highly experienced team



Inflammation


Building a Broad Inflammation and Fibrosis Portfolio with Galapagos Beyond Filgotinib



Doubles Gilead's R&D footprint and accelerates transformational therapy development


9 clinical programs^{1,2}

>20 pre-clinical programs²





Selected programs



Lighter shade - new or progressed to next phase since Q4'19



Anticipated Milestones Through 2021

GLPG-1690²

P3 IPF futility analysis data

Filgotinib (moved from H2'20) P3 enrollment completion for CD

GLPG-1972¹

P2 OA data

Filgotinib

Expected RA approvals in U.S., Europe, Japan


Filgotinib

MANTA/MANTA-RAy enrollment completion

H2 2020 2021



Inflammatory Disease Pipeline



Lighter shade - new or progressed to next phase since Q4'19

